Home / Blog
The research library
The blog: real science, stamped prices, and the topics ad-funded sites skim
Thirty-nine guides are live — every one of them at roughly 2,000 words or more of researched, sourced prose — with the roadmap running to 250, weighted the way the search demand actually runs: 80% tirzepatide, 10% semaglutide, 10% the frontier. Every article opens with a liftable quick answer, carries Article + FAQ + speakable schema, cites primary sources, and shows a pending badge until Dr. Goher's review of that specific piece is complete — the gating rule that keeps the badge worth something.
New — the practical library
The practical library: nineteen guides — food, access, results, and the fraud file
Cheaper Zepbound alternatives →
Five real lanes, priced — coverage doors, the $50 Bridge, $299 vials, $149 pills, the verified floor — and the two non-alternatives named.
What to eat on tirzepatide →
Protein-first plates, the three regret patterns, hydration as a habit — eating that works with the drug.
Tirzepatide and alcohol →
No formal ban — but slowed digestion, pancreatitis math, and the strange fading of the urge itself.
Protein & muscle on GLP-1s →
The 1.2–1.6 g/kg target, the training minimum, and keeping what the scale can't see.
How to inject tirzepatide →
Site rotation, the actual technique, and the five mistakes behind most sore-spot complaints.
Travel & storage rules →
Refrigeration tolerances, TSA, time zones, and what to do when medication gets warm.
Missed a dose? →
The 4-day rule, what happens in the gap, and when a long lapse means restarting lower.
Pregnancy & birth control →
The pre-conception stop, the labeled oral-contraceptive interaction, and fertility's surprise comeback.
Tirzepatide for PCOS →
Off-label but mechanistically apt: insulin resistance, cycles, fertility, and access routes.
Do I qualify? →
BMI rules, the comorbidities that count, the hard stops, and the three gatekeepers' rulebooks.
The thyroid warning, explained →
What the rodent finding means and doesn't, the family question to ask, the four symptoms that matter.
Prior authorization playbook →
The documentation that wins, the appeal ladder with clocks, and the OSA and diabetes side doors.
Insurance coverage map 2026 →
Commercial, Medicare, Medicaid, savings cards — what each plan type actually pays.
Results timeline →
Week 1 to month 12: appetite in days, the slow build, the steep middle, the honest plateau.
Weight loss by dose →
15% at 5 mg, 19.5% at 10, 20.9% at 15 — and why the right dose is the lowest one that works.
Constipation relief ladder →
The GIP mechanism and the fluids→fiber→movement→osmotic ladder that solves most cases.
The seven scams of 2026 →
Fake pharmacies, counterfeit pens, coupon harvesters — and the 60-second checks that defeat them.
Oral Wegovy, explained →
The $149 SNAC pill: the ritual that is the mechanism, and who it genuinely suits.
Half-life & washout →
The 5-day half-life and the six decisions it drives, from missed doses to surgery holds.
Every program, every true monthly cost, every status — the full ledger in prose.
Read the article →All five legal paths priced — $25 insured to $499 vials — with the seven walk-away red flags.
Read the article →The (mg ÷ mg/mL) × 100 formula, full charts at 5/10/17 mg/mL, and the provider-switch trap.
Read the article →The 2.5 mg restart, the 7-day handoff, SURMOUNT-5's math, and both directions of the switch.
Read the article →The five-check diagnostic order, the audit worksheet, and the plateau that's the destination.
Read the article →Hydrogen-sulfide fermentation, the ordered relief stack, a 7-day menu, and the red-flag lines.
Read the article →Licensure, not bans: the pairing fix, the 10-question support script, and the moving wrinkle.
Read the article →SURMOUNT-OSA's numbers, the coverage back door, home tests, and the CPAP cadence.
Read the article →Telogen effluvium's timeline, the pace-protein-plate-panel protocol, and the wash-day audit.
Read the article →The first real GLP-1 pill — $149–349/mo — and what it does to the tablet fantasy.
Read the article →Who qualifies, the short covered list, and the exclusions that feel backwards.
Read the article →Definition, four legal dates, and the base-vs-salt chemistry trap.
Read the article →A 4,814-dalton peptide vs your digestive tract — and the approved pill that proves the point.
Read the article →Slow titration vs minimum-effective dosing vs a pricing tier in a lab coat.
Read the article →SURMOUNT-5's 20.2% vs 13.7% — and the SELECT cardiovascular card.
Read the article →SURMOUNT-4's withdrawal data and the maintenance-plan unit of cost.
Read the article →Four risk layers, each with the check that shrinks it.
Read the article →They're scheduled, not random: the titration calendar and the playbook.
Read the article →24.2% in phase 2 — and zero legal ways to buy it. Science and scam ecosystem.
Read the article →Four cash routes priced honestly — including the $149 pill and the $50 Medicare lane.
Read the article →